Generative AI offers much greater potential than as a ‘point’ solution to a single problem, says Daniel Jamieson, CEO & founder of Biorelate.
Its broader appeal is as a smart decision support tool, joining up the R&D organisation and helping to hone drug selection.
The chance to employ deep-learning algorithms to distil complex knowledge into easily digestible summaries is understood in many industries now, but less so in life sciences.
This is a shame given the immense potential of generative AI (GenAI) to more accurately target drug discovery and its outcomes.
Check out the rest of this feature here
